Alain Sainsot
Angel Investor
Toulouse, France
Alain Sainsot is a seed investor in Toulouse focused on Biotechnology and Medical. Alain Sainsot is the current President and Chief Executive Officer of GTP Bioways. He previously worked at AMATSIGROUP as a President. Alain Sainsot attended ISG Higher Institute of Management.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Alain Sainsot invests in
Stages Alain Sainsot invests in
Countries Alain Sainsot invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Wellness 1 (50%)
- Health Care 1 (50%)
- Manufacturing 1 (50%)
Stage
- Seed 1 (50%)
- Private Equity 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform. | $3.9M / Private Equity / May 16, 2018 | ||
| Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwideunderstand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues.Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest.Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects. | $282.9K / Seed / May 18, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Alain Sainsot invest in?
Alain Sainsot invests primarily in Biotechnology, Medical and Wellness startups, most often at Seed and Private Equity stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alain Sainsot?
Public channels for Alain Sainsot include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alain Sainsot last invest?
The most recent investment recorded for Alain Sainsot closed in May 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
